Analyst Reco. Amgen Inc.

Equities

AMGN

US0311621009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
270 ^USD	+0.22%		+0.39%	-6.26%

Apr. 26	Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe	MT
Apr. 26	Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating	Apr. 17	MT
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	Apr. 15	MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	Apr. 15	MT
BMO Lowers Price Target on Amgen to $336 From $343	Apr. 12	MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating	Apr. 09	MT
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
Fed officials fail to convince investors, who are focused on earnings	Feb. 07
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating	Feb. 07	MT
TD Cowen Adjusts Amgen Price Target to $370 From $336, Maintains Outperform Rating	Feb. 07	MT
Leerink Partners Downgrades Amgen to Market Perform From Outperform, Adjusts Price Target to $324 From $318	Feb. 07	MT
Baird Adjusts Amgen Price Target to $215 From $185, Maintains Underperform Rating	Feb. 07	MT
Goldman Sachs Adjusts Amgen Price Target to $350 From $313, Maintains Buy Rating	Feb. 07	MT
Morgan Stanley Trims Price Target on Amgen to $278 From $281 After Higher-Than-Expected Q4 2023 Results, Keeps Equalweight Rating	Feb. 07	MT
RBC Boosts Price Target on Amgen to $329 From $303 After Q4 Beats, Notes 'Positive' Pipeline Posture; Keeps Outperform Rating	Feb. 07	MT
That's good enough for investors	Feb. 06
MORNING BID AMERICAS-Rates rebound cools, China commands rally	Feb. 06	RE
Deutsche Bank Adjusts Amgen Price Target to $285 From $240, Maintains Hold Rating	Feb. 02	MT
UBS Trims Amgen Price Target to $314 From $315, Maintains Neutral Rating	Jan. 29	MT
RBC Lifts Price Target on Amgen to $303 From $300, Keeps Outperform Rating	Jan. 03	MT
Daiwa Securities Upgrades Amgen to Buy From Neutral, Price Target is $320	Dec. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amgen Inc.

Equities

AMGN

US0311621009

Analyst Reco.

Filters